Clinical Evaluation of Systemic Inflammation Markers in Patients Diagnosed with Pulmonary Tuberculosis
- 15 March 2026
- journal article
- Published by Bozok Tip Dergisi in Bozok Tıp Dergisi
- Vol. 16 (1) , 37-47
Abstract
Objective: This study aimed to investigate the levels of systemic inflammation markers—including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), hematological ratios, and complete blood count parameters—in individuals diagnosed with pulmonary tuberculosis (TBC). The clinical significance of these biomarkers in the diagnosis, disease activity, and treatment response was evaluated, and their associations with age, sex, and comorbidities were also analyzed.Materials and Methods: Following ethics approval (2025-GOKAEK-2517), hospital records of patients aged 18–80 years diagnosed with pulmonary tuberculosis between 2023 and 2025 at Yozgat Bozok University and Sivas Cumhuriyet University were retrospectively reviewed. The control group consisted of healthy individuals who presented during the same period. Hemogram parameters, CRP, ESR, and the Systemic Immune-Inflammation Index (SII) were assessed, and statistical analyses were performed using SPSS v22.0.Results: A total of 134 individuals (67 TBC and 67 controls) were included. In the TBC group, 70.1% were male, and the mean age was 48.76 ± 18.01 years. Comorbidities were present in 70.1% of patients, most commonly COPD, hypertension, and coronary artery disease. The TBC group demonstrated significantly higher leukocyte, neutrophil, monocyte, platelet, CRP, ESR, and SII levels, while hemoglobin and lymphocyte levels were significantly lower (all p < 0.0001). Although the mean SII value was elevated (2772.51 ± 4004.20), it did not show a significant association with diagnostic test results or clinical outcomes.Conclusion: The markedly elevated SII levels in patients with pulmonary tuberculosis suggest that this index may serve as a potential biomarker reflecting increased systemic inflammation. However, its limited correlation with diagnostic and clinical endpoints indicates that it should be considered a supportive—not standalone—parameter in clinical evaluation.Keywords
Funding Information
- None
This publication has 30 references indexed in Scilit:
- Characteristics and in-hospital outcomes of clinically diagnosed tuberculosis patients in a high-burden setting: A five-year retrospective analysisRespiratory Medicine, 2025
- Tuberculosis in Turkiye: Epidemiological insights and recommendations for progressEuropean Journal of Clinical Microbiology & Infectious Diseases, 2025
- Insights from the 2024 WHO Global Tuberculosis Report – More Comprehensive Action, Innovation, and Investments required for achieving WHO End TB goalsInternational Journal of Infectious Diseases, 2024
- Host blood protein biomarkers to screen for tuberculosis disease: a systematic review and meta-analysisJournal of Clinical Microbiology, 2024
- Biomarkers in diagnosing and therapeutic monitoring of tuberculosis: a reviewAnnals of Medicine, 2024
- A Systematic Review of Potential Biomarkers for Bacterial Burden and Treatment Efficacy Assessment in Tuberculosis Platform-Based Clinical TrialsThe Journal of Infectious Diseases, 2023
- Clinical manifestations and immune response to tuberculosisWorld Journal of Microbiology and Biotechnology, 2023
- Role of latent tuberculosis infection on elevated risk of cardiovascular disease: a population-based cohort study of immigrants in British Columbia, Canada, 1985–2019Epidemiology and Infection, 2023
- Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosisCochrane Database of Systematic Reviews, 2021
- Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic reviewThe Lancet Infectious Diseases, 2006